Title:Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Volume: 18
Issue: 29
Author(s): Paulus S. Rommer, Robert Patejdl and Uwe K. Zettl
Affiliation:
Keywords:
Immune-mediated CNS disease, monoclonal antibodies, natalizumab, rituximab, alemtuzumab, daclizumab, multiple sclerosis (MS), neuromyelitis optica (NMO), chronic inflammatory demyelinating polyneuropathy (CIDP), inclusion body myositis (IBM).
Abstract: Over the past 25 years, monoclonal antibodies (mAb) have become important elements in the therapeutic concepts for numerous
clinical specialities, including oncology, gastroenterology, hemostaseology and endocrinology. One of the most dynamic fields of
their use is the treatment of autoimmune diseases. Although the number of existing mAb interfering with the immune system has increased
remarkably and many studies have yielded encouraging results in the treatment of neuroimmunological diseases, their clinical use
is still limited compared with standard treatments. The only mAb which has been approved for a neuroimmunological disease by now is
natalizumab for the treatment of relapsing-remitting multiple sclerosis (RRMS). This article gives an overview on mAb that are currently
in use or under investigation for treating neuroimmunological diseases like multiple sclerosis (MS), neuromyelitis optica (NMO), chronic
inflammatory demyelinating polyneuropathy (CIDP), inclusion body myositis (IBM), dermatomyositis, polymyositis, opsoclonusmyoclonus
syndrome (OMS), multifocal motor neuropathy (MMN), anti-myelin-glycoprotein neuropathy (Anti-MAG), stiff person syndrome
and myasthenia gravis (MG).
